Are the benefits of transdermal estradiol patch or cream therapy demonstrated in women over 70 years of age?

Transdermal Estradiol Therapy in Women Over 70: No Demonstrated Benefits for Chronic Disease Prevention

The use of transdermal estradiol patches or creams for chronic disease prevention in women over 70 is not recommended and lacks evidence of benefit, with demonstrated harms including increased stroke risk, dementia, and thromboembolic events. 1

Evidence Against Use in Women Over 70

The USPSTF provides Grade D recommendations (recommending against use) for both estrogen-alone and combined estrogen-progestin therapy for chronic disease prevention in postmenopausal women 1. This recommendation is particularly relevant for women over 70, as the evidence shows:

Increased Harms in Older Women

Women over 65 years face significantly elevated risks:

• Stroke risk increases with both estrogen-alone and estrogen-plus-progestin therapy in women >65 years 2
• Probable dementia risk doubles (HR 2.05 for estrogen-plus-progestin; HR 1.49 for estrogen-alone) in women aged 65-79 years 2
• The absolute risk of probable dementia increases from 25 to 37 cases per 10,000 women-years with estrogen-alone 2

Age-Specific Subgroup Analysis

Subgroup analyses from the Women's Health Initiative demonstrated that women 70 years or older had the highest cardiovascular risks, with no statistically significant protective effects in younger age groups 3. The data specifically shows women 20+ years post-menopause or aged ≥70 years had elevated CHD risk, though differences weren't always statistically significant.

Route of Administration Does Not Change the Recommendation

While the question specifically asks about patches and creams (transdermal delivery), the evidence base primarily addresses oral formulations. However:

• The USPSTF guidelines apply regardless of delivery method for chronic disease prevention 1
• The FDA labeling for transdermal estradiol explicitly states insufficient data exists for women over 65: "There have not been sufficient numbers of geriatric patients involved in studies utilizing estradiol vaginal cream USP 0.01% to determine whether those over 65 years of age differ from younger subjects" 2
• Studies examining transdermal estradiol in older women (ages 60-80) showed no cognitive benefits 4 and only marginal effects on reaction time 5

Clinical Context: When This Does NOT Apply

This recommendation is specifically for chronic disease prevention only. The USPSTF explicitly excludes:

• Treatment of menopausal symptoms (hot flashes, vaginal dryness) 1
• Women under 50 with surgical menopause 1

For symptomatic relief of vulvovaginal atrophy in women over 70, low-dose vaginal estrogen preparations may still be appropriate, but this is a different clinical indication entirely.

Critical Pitfall to Avoid

Do not confuse chronic disease prevention with symptom management. A 72-year-old woman with severe vaginal atrophy causing dyspareunia may benefit from low-dose vaginal estrogen for symptom relief—this is distinct from initiating systemic hormone therapy for osteoporosis or cardiovascular prevention, which is contraindicated.

The Bottom Line for Women Over 70

For chronic disease prevention: Do not initiate transdermal estradiol therapy. The harms (stroke, dementia, thromboembolism) outweigh any potential benefits (fracture reduction), particularly as age-related risks compound 1, 3, 2. The evidence shows increased absolute risk with advancing age, making women over 70 the least appropriate candidates for systemic hormone therapy for preventive purposes.